Estudo randomizado | Em pacientes críticos hospitalizados com Covid-19, anticoagulação em dose terapêutica com heparina não resultou em melhores desfechos em comparação com a tromboprofilaxia farmacológica usual.

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 – New England Journal of Medicine

Editorial: Surviving Covid-19 with Heparin?

Comentários:

Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients – National Institutes of Health

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD

Comentário no Twitter

Anticoagulation did not improve hospital survival in critically Ill patients with #COVID19. https://t.co/E8RXE01jbF pic.twitter.com/9idGxgbUas

— NEJM (@NEJM) August 4, 2021